论文部分内容阅读
目的评价阿德福韦酯(贺维力)片10mg/d治疗HBeAg阳性慢性乙型病毒性肝炎患者48周的疗效和安全性。方法入选的36例患者每日口服阿德福韦酯片10mg,每日1次,连服48周。主要疗效评估指标为血清HBV DNA的变化情况,次要疗效评估指标包括:丙氨酸转氨酶(ALT)的复常率,HBeAg阴转率和HBeAg的血清转化率。结果治疗12、24、36、48周时HBV DNA中位数水平较基线分别降低2.68log10 copies/ml、2.92log10 copies/ml、3.46log10 copies/ml、4.11log10 copies/ml;HBV DNA转阴率分别为19.44%、30.56%、45.71%、51.51%;ALT复常率分别为50%、63.89%、71.14、78.79%;HBeAg阴转率分别为2.78%、8.33%、11.43%、15.16%。结论阿德福韦酯(贺维力)10mg/d剂量治疗48周HBeAg阳性的慢性乙型病毒性肝炎患者有效、安全。
Objective To evaluate the efficacy and safety of adefovir dipivoxil 10 mg / d for 48 weeks in patients with HBeAg-positive chronic hepatitis B virus. Methods selected 36 patients daily oral adefovir dipivoxil 10mg, 1 day, and even for 48 weeks. The main curative effect index is the change of serum HBV DNA. The secondary curative effect indexes include the normalization rate of alanine aminotransferase (ALT), the negative rate of HBeAg and the seroconversion rate of HBeAg. Results The HBV DNA median levels decreased by 2.68log10 copies / ml, 2.92log10 copies / ml, 3.46log10 copies / ml, 4.11log10 copies / ml respectively compared with the baseline at 12, 24, 36, The rates of ALT normalization were 50%, 63.89%, 71.14% and 78.79%, respectively. The negative conversion rates of HBeAg were 2.78%, 8.33%, 11.43% and 15.16% respectively. Conclusions Adefovir dipivoxil (Hever force) 10mg / d dose for 48 weeks HBeAg-positive patients with chronic hepatitis B effective and safe.